FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Dec. 20, 2005--Andrx Corporation (Nasdaq:ADRX) (“Andrx” or “Company”) announced today that it has filed a patent infringement lawsuit in the U.S. District Court for the Southern District of Florida against GlaxoSmithKline plc and SmithKline Beecham Corporation (collectively “Glaxo”). The Company believes Glaxo’s currently marketed formulation of Wellbutrin XL(R) 150mg infringes Andrx Pharmaceuticals, LLC’s U.S. Patent No. 6,905,708. The lawsuit seeks treble damages and to enjoin Glaxo and those acting in concert with it from making, importing, using, selling and/or offering for sale in the United States its Wellbutrin XL 150mg product.
